AbbVie (NYSE:ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. AbbVie Inc. (NYSE:ABBV) net profit margin is 21.80% and weekly performance is 1.04%. On last trading day company shares ended up $52.69. Analysts mean target price for the company is $55.75. AbbVie Inc. (NYSE:ABBV) distance from 50-day simple moving average (SMA50) is 3.60%.
A Maryland federal judge on Wednesday found that Classen Immunotherapies Inc.’s claims that Biogen Idec Inc. (NASDAQ:BIIB) infringed its patents for evaluating a vaccine immunization schedule were objectively baseless, dismissing Biogen from the case and granting its request for attorneys’ fees. Biogen Idec Inc. (NASDAQ:BIIB) shares fell -2.35% in last trading session and ended the day on $289.53. BIIB gross Margin is 86.90% and its return on assets is 16.60%.Biogen Idec Inc. (NASDAQ:BIIB) quarterly performance is -11.90%.
On April 29, 2014, Cell Therapeutics, Inc. (NASDAQ:CTIC) issued a press release in Italy announcing, among other things, its financial results for the quarter ended March 31, 2014 and providing certain additional information requested by CONSOB, the Italian securities regulatory authority, about the Company (the “Quarterly Italian Press Release”). Cell Therapeutics Inc. (NASDAQ:CTIC) shares moved down -1.83% in last trading session and was closed at $2.68, while trading in range of $2.58 – $2.72. Cell Therapeutics Inc. (NASDAQ:CTIC) year to date (YTD) performance is 40.31%.
Basel-based Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) said sales of new breast cancer treatments Perjeta and Kadcyla rose smartly as they gained more acceptance from doctors, even as the performance of older drugs, such as hepatitis treatment Pegasys, weakened. Sales of Xeloda, a cancer drug, also slowed. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) ended the last trading day at $37.40.
Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) recorded net product sales for BELVIQ of $8.4 million in the first quarter of 2014. Eisai announced plans to add another 200 representatives to its sales force for BELVIQ by July 2014, increasing the number of representatives to approximately 600. Eisai believes this expansion of the sales force will enable them to reach approximately 90,000 physicians in the United States. This increase is in addition to the 200 sales representatives for BELVIQ that Eisai added around the end of 2013. On last trading day company shares ended up $39.61.